MedPath

YALE UNIVERSITY

YALE UNIVERSITY logo
🇺🇸United States
Ownership
Private
Established
1701-10-09
Employees
10K
Market Cap
-
Website
http://www.yale.edu

CHG Dressings in Children With Central Lines

Not Applicable
Terminated
Conditions
Children With Central Venous Access
Interventions
Other: Tegaderm CHG clear dressing
Other: Standard clear Tegaderm dressing
First Posted Date
2013-10-07
Last Posted Date
2016-05-13
Lead Sponsor
Yale University
Target Recruit Count
16
Registration Number
NCT01955226
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

Early Phase 1
Terminated
Conditions
Type 1 Diabetes
Interventions
Device: Continuous glucose sensor
Device: Insupatch
First Posted Date
2013-10-01
Last Posted Date
2020-03-09
Lead Sponsor
Yale University
Target Recruit Count
11
Registration Number
NCT01954459
Locations
🇺🇸

Yale University School of Medicine, New Haven, Connecticut, United States

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

Early Phase 1
Completed
Conditions
Type 1 Diabetes
Interventions
Device: ePID closed loop system
Drug: Lispro-PH20
First Posted Date
2013-09-18
Last Posted Date
2022-05-24
Lead Sponsor
Yale University
Target Recruit Count
13
Registration Number
NCT01945099
Locations
🇺🇸

Yale University School of Medicine, New Haven, Connecticut, United States

The Development of a Domestic Violence Perpetrator Collusion Measurement Tool

Not Applicable
Completed
Conditions
Intimate Partner Violence (IPV)
First Posted Date
2013-09-16
Last Posted Date
2023-08-30
Lead Sponsor
Yale University
Target Recruit Count
72
Registration Number
NCT01942616
Locations
🇺🇸

Michigan State University, East Lansing, Michigan, United States

🇺🇸

Yale University, New Haven, Connecticut, United States

🇺🇸

Loyola University New Orleans, New Orleans, Louisiana, United States

and more 1 locations

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

Phase 2
Completed
Conditions
Restless Leg Syndrome
Interventions
First Posted Date
2013-08-29
Last Posted Date
2016-03-21
Lead Sponsor
Yale University
Target Recruit Count
24
Registration Number
NCT01931878
Locations
🇺🇸

Yale Physcian Building, New Haven, Connecticut, United States

IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation

Phase 2
Terminated
Conditions
Pain
Interventions
First Posted Date
2013-08-29
Last Posted Date
2015-12-31
Lead Sponsor
Yale University
Target Recruit Count
12
Registration Number
NCT01931865
Locations
🇺🇸

Yale Physician Building, New Haven, Connecticut, United States

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

Phase 2
Completed
Conditions
Type I Diabetes
Interventions
First Posted Date
2013-08-23
Last Posted Date
2020-03-19
Lead Sponsor
Yale University
Target Recruit Count
79
Registration Number
NCT01928329
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 5 locations

Atypical Lesions of the Breast: Close Observation Versus Excision (ALCOVE)

Completed
Conditions
Atypical Ductal Hyperplasia (ADH) of the Breast
First Posted Date
2013-08-19
Last Posted Date
2019-01-28
Lead Sponsor
Yale University
Target Recruit Count
9
Registration Number
NCT01925586
Locations
🇺🇸

Yale University & Smilow Breast Center at Yale New Haven Hospital, New Haven, Connecticut, United States

iPad Application to Treat Prosodic Deficits in Students With Communication Disorders

Not Applicable
Completed
Conditions
Communication Disorders
Autism
Interventions
Behavioral: iPad Application
First Posted Date
2013-08-07
Last Posted Date
2016-06-14
Lead Sponsor
Yale University
Target Recruit Count
200
Registration Number
NCT01917864
Locations
🇺🇸

Yale Child Study Center, New Haven, Connecticut, United States

Translational Neuroscience Optimization of GlyT1 Inhibitor

Phase 2
Completed
Conditions
Cognitive Impairments Associated With Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2013-07-30
Last Posted Date
2024-08-19
Lead Sponsor
Yale University
Target Recruit Count
71
Registration Number
NCT01911676
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath